Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum

Experimental Neurology

Volumn 208, Issue 1, 2007, Pages 73-79

  Mattsson, Anna ^a   Olson, Lars ^a   Svensson, Torgny H ^a   Schilström, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Accumbens; Cholinergic; Cortex; Muscarinic; Nucleus basalis magnocellularis; Saporin; Schizophrenia

Indexed keywords

AMPHETAMINE; CHOLINERGIC RECEPTOR; DOPAMINE; IMMUNOGLOBULIN G; MUSCARINIC AGENT; NICOTINE; OXOTREMORINE; SAPORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINE RELEASE; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NEOCORTEX; NONHUMAN; NUCLEUS ACCUMBENS; OLIVARY NUCLEUS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; THALAMOCORTICAL TRACT;

AMPHETAMINE; ANIMALS; CHOLINERGIC FIBERS; CORPUS STRIATUM; DENERVATION; DOPAMINE; DOPAMINE AGENTS; MICRODIALYSIS; MOTOR ACTIVITY; NEOCORTEX; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 35349023677     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.07.012     Document Type: Article

References (48)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155 (1998) 761-767
2. Adler L.E., Waldo M.C., and Freedman R. Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses. Biol. Psychiatry 20 (1985) 1284-1296
3. Andersen M.B., Fink-Jensen A., Peacock L., Gerlach J., Bymaster F., Lundbaek J.A., and Werge T. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28 (2003) 1168-1175
4. Angrist B., Sathananthan G., Wilk S., and Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11 (1974) 13-23
5. Bartus R.T., Dean R.L.D., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
6. Berntson G.G., Shafi R., and Sarter M. Specific contributions of the basal forebrain corticopetal cholinergic system to electroencephalographic activity and sleep/waking behaviour. Eur. J. Neurosci. 16 (2002) 2453-2461
7. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2569-2574
8. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1 (1988) 179-186
9. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
10. Carr D.B., and Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J. Neurosci. 20 (2000) 3864-3873
11. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., and Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. 73 (1999) 1590-1597
12. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 48 (2000) 381-388
13. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 158 (2001) 918-925
14. Cummings J.L., McRae T., and Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry 14 (2006) 605-612
15. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., and Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol. Psychiatry 1 (1996) 54-58
16. Devanand D.P., Marder K., Michaels K.S., Sackeim H.A., Bell K., Sullivan M.A., Cooper T.B., Pelton G.H., and Mayeux R. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am. J. Psychiatry 155 (1998) 1512-1520
17. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5274-5278
18. Freedman R., Hall M., Adler L.E., and Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 38 (1995) 22-33
19. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., and Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 587-592
20. Gerber D.J., Sotnikova T.D., Gainetdinov R.R., Huang S.Y., Caron M.G., and Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15312-15317
21. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
22. Grenhoff J., Aston-Jones G., and Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128 (1986) 351-358
23. Guan Z.Z., Zhang X., Blennow K., and Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. NeuroReport 10 (1999) 1779-1782
24. Heckers S., Ohtake T., Wiley R.G., Lappi D.A., Geula C., and Mesulam M.M. Complete and selective cholinergic denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor. J. Neurosci. 14 (1994) 1271-1289
25. Herron P., Li Z., and Schweitzer J.B. Effects of cholinergic depletion on evoked activity in the cortex of young and aged rats. Int. J. Dev. Neurosci. 16 (1998) 633-643
26. Herron P., and Schweitzer J.B. Effects of cholinergic depletion on neural activity in different laminae of the rat barrel cortex. Brain Res. 872 (2000) 71-76
27. Ichikawa J., Chung Y.C., Li Z., Dai J., and Meltzer H.Y. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 958 (2002) 176-184
28. Jeste D.V., and Finkel S.I. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am. J. Geriatr. Psychiatry 8 (2000) 29-34
29. Karnovsky M.J., and Roots L. A "direct-coloring" thiocholine method for cholinesterase. J. Histochem. Cytochem. 12 (1964) 219-221
30. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
31. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 31 (2000) 371-384
32. Mattsson A., Ogren S.O., and Olson L. Facilitation of dopamine-mediated locomotor activity in adult rats following cholinergic denervation. Exp. Neurol. 174 (2002) 96-108
33. Mattsson A., Pernold K., Ogren S.O., and Olson L. Loss of cortical acetylcholine enhances amphetamine-induced locomotor activity. Neuroscience 127 (2004) 579-591
34. Mattsson A., Lindqvist E., Ögren S.O., and Olson L. Increased phencyclidine-induced hyperactivity following cortical cholinergic denervation. NeuroReport 16 (2005) 1815-1819
35. Murase S., Grenhoff J., Chouvet G., Gonon F.G., and Svensson T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett. 157 (1993) 53-56
36. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur. J. Pharmacol. 195 (1991) 63-73
37. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., Egan M.F., Coppola R., and Weinberger D.R. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 160 (2003) 118-127
38. Rossner S., Schliebs R., and Bigl V. 192IgG-saporin-induced immunotoxic lesions of cholinergic basal forebrain system differentially affect glutamatergic and GABAergic markers in cortical rat brain regions. Brain Res. 696 (1995) 165-176
39. Schilström B., Nomikos G.G., Nisell M., Hertel P., and Svensson T.H. N-methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82 (1998) 781-789
40. * nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse 38 (2000) 375-383
41. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D., Jeppesen L., Sheardown M.J., Sauerberg P., and Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res. 42 (2000) 249-259
42. Svensson T.H. Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clin. Neurosci. Res. 3 (2003) 34-46
43. Sweet R.A., Nimgaonkar V.L., Devlin B., and Jeste D.V. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol. Psychiatry 8 (2003) 383-392
44. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., McKinzie D.L., Felder C., and Nomikos G.G. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 18 (2004) 1410-1412
45. Walsh T.J., Kelly R.M., Dougherty K.D., Stackman R.W., Wiley R.G., and Kutscher C.L. Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: cholinergic and non-cholinergic effects following i.c.v. injection. Brain Res. 702 (1995) 233-245
46. White K.E., and Cummings J.L. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr. Psychiatry 37 (1996) 188-195
47. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., and Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 (1982) 1237-1239
48. Wiley R.G., Oeltmann T.N., and Lappi D.A. Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. Brain Res. 562 (1991) 149-153